Shanghai Pulmonary Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website: http://med.tongji.edu.cn/english/article.asp?article_id=6219&category_id=2098&root_id=2

Clinical Trials

Anti-PD1 Precision Therapy Shows Promise in Unresectable Stage III NSCLC Trial

3 months ago

A phase II umbrella trial demonstrated that anti-PD1 based precision induction therapy achieved a 61.7% major pathological response rate in patients with unresectable stage III non-small cell lung cancer.

Home Terms & Conditions Privacy Policy